{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T08:25:03Z","timestamp":1794558303979,"version":"4.9.1"},"reference-count":22,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.clgc.2026.102561","type":"journal-article","created":{"date-parts":[[2026,4,12]],"date-time":"2026-04-12T16:34:06Z","timestamp":1776011646000},"page":"102561","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Comparative and Critical Analysis of Immune-based Combinations for First-line Treatment of Metastatic Renal Cell Carcinoma"],"prefix":"10.1016","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5011-5477","authenticated-orcid":false,"given":"Tomer","family":"Meirson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luciano","family":"Mutti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel A","family":"Goldstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamar","family":"Barkan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raz","family":"Mutai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gal","family":"Markel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Goldman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9474-4232","authenticated-orcid":false,"given":"Laura","family":"Cosmai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7743-741X","authenticated-orcid":false,"given":"Mimma","family":"Rizzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2412-1563","authenticated-orcid":false,"given":"Camillo","family":"Porta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clgc.2026.102561_bib0001","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.annonc.2024.05.537","article-title":"Renal cell carcinoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"35","author":"Powles","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clgc.2026.102561_bib0002","unstructured":"NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). Kidney cancer. Version 1, 2024. Available at: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/kidney.pdf. Accessed: March 30, 2024."},{"key":"10.1016\/j.clgc.2026.102561_bib0003","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.euros.2020.11.003","article-title":"Treatment of advanced renal cell carcinoma: immunotherapies have demonstrated overall survival benefits while targeted therapies have not","volume":"22","author":"Hemminki","year":"2020","journal-title":"Eur Urol Open Sci"},{"key":"10.1016\/j.clgc.2026.102561_bib0004","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","article-title":"Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma","volume":"378","author":"Motzer","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clgc.2026.102561_bib0005","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1056\/NEJMoa2026982","article-title":"Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma","volume":"384","author":"Choueiri","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clgc.2026.102561_bib0006","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1056\/NEJMoa1816714","article-title":"Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma","volume":"380","author":"Rini","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clgc.2026.102561_bib0007","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1056\/NEJMoa2035716","article-title":"Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma","volume":"384","author":"Motzer","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clgc.2026.102561_bib0008","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.1490","article-title":"Comparison of 3 randomized clinical trials of frontline therapies for malignant pleural mesothelioma","volume":"5","author":"Meirson","year":"2022","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.clgc.2026.102561_bib0009","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.17675","article-title":"Survival-inferred Fragility Index of phase 3 clinical trials evaluating immune checkpoint inhibitors","volume":"3","author":"Bomze","year":"2020","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.clgc.2026.102561_bib0010","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.55630","article-title":"Reanalysis of urothelial cancer chemoimmunotherapy trials with differential censoring","volume":"8","author":"Meirson","year":"2025","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.clgc.2026.102561_bib0011","doi-asserted-by":"crossref","first-page":"861","DOI":"10.21037\/hbsn-21-118","article-title":"Systemic review of the robustness of randomized controlled trials for the treatment of cholangiocarcinoma in three domains: survival-inferred fragility index, restricted mean survival time, and the spin effect","volume":"11","author":"Horesh","year":"2022","journal-title":"Hepatobiliary Surg Nutr"},{"key":"10.1016\/j.clgc.2026.102561_bib0012","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.ejca.2021.04.044","article-title":"Informative censoring of surrogate end-point data in phase 3 oncology trials","volume":"153","author":"Gilboa","year":"2021","journal-title":"Eur J Cancer"},{"issue":"2","key":"10.1016\/j.clgc.2026.102561_bib0013","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.ijrobp.2025.02.006","article-title":"Challenges in interpreting survival metrics in clinical trials: the utility of restricted mean survival analyses","volume":"122","author":"Averbuch","year":"2025","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.clgc.2026.102561_bib0014","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1001\/jamaoncol.2017.2797","article-title":"Interpretability of cancer clinical trial results using restricted mean survival time as an alternative to the hazard ratio","volume":"3","author":"Pak","year":"2017","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.clgc.2026.102561_bib0015","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1186\/1471-2288-13-152","article-title":"Restricted mean survival time: an alternative to the hazard ratio for the design and analysis of randomized trials with a time-to-event outcome","volume":"13","author":"Royston","year":"2013","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.clgc.2026.102561_bib0016","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1001\/jamasurg.2021.0534","article-title":"ISPOR reporting guidelines for comparative effectiveness research","volume":"156","author":"Massarweh","year":"2021","journal-title":"JAMA Surg"},{"issue":"2","key":"10.1016\/j.clgc.2026.102561_bib0017","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1177\/0145445516673998","article-title":"Intercoder reliability and validity of WebPlotDigitizer in extracting graphed data","volume":"41","author":"Drevon","year":"2017","journal-title":"Behav Modif"},{"issue":"10","key":"10.1016\/j.clgc.2026.102561_bib0018","doi-asserted-by":"crossref","DOI":"10.1016\/S1470-2045(19)30582-0","article-title":"A critique of the fragility index","volume":"20","author":"Bomze","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clgc.2026.102561_bib0019","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1471-2288-12-9","article-title":"Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan\u2013Meier survival curves","volume":"12","author":"Guyot","year":"2012","journal-title":"BMC Med Res Methodol"},{"issue":"35","key":"10.1016\/j.clgc.2026.102561_bib0020","doi-asserted-by":"crossref","first-page":"4095","DOI":"10.1200\/JCO.22.00535","article-title":"Overall survival, progression-free survival, and tumor response benefit supporting initial US Food and Drug Administration approval and indication extension of new cancer drugs, 2003-2021","volume":"40","author":"Michaeli","year":"2022","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.clgc.2026.102561_bib0021","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.6498","article-title":"Assessment of median and mean survival time in cancer clinical trials","volume":"6","author":"Das","year":"2023","journal-title":"JAMA Netw Open"},{"issue":"9","key":"10.1016\/j.clgc.2026.102561_bib0022","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.24728","article-title":"Use of second-line immunotherapy in control arms of randomized clinical trials in kidney cancer: a systematic review","volume":"4","author":"Sharp","year":"2021","journal-title":"JAMA Netw Open"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767326000613?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767326000613?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T08:14:49Z","timestamp":1794557689000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767326000613"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":22,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S1558767326000613"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2026.102561","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparative and Critical Analysis of Immune-based Combinations for First-line Treatment of Metastatic Renal Cell Carcinoma","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2026.102561","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102561"}}